Enhanced inhibition of murine prostatic carcinoma growth by immunization with or administration of viable human umbilical vein endothelial cells and CRM197

Brazilian Journal of Medical and Biological Research

Volumn 44, Issue 2, 2011, Pages 140-148

  Zhang, Huiyong ^a   Lu, Yong ^b   Mekoo, Didier ^b   Zhang, Yu ^b   Fang, Jing ^c   Cao, Rongyue ^b   Liu, Jingjing ^b  

^a XINXIANG MEDICAL UNIVERSITY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c RESEARCH INSTITUTE OF FORESTRY   (China)

Author keywords

CRM197; Human umbilical vein endothelial cells; Immunization; RM 1 prostatic carcinoma

Indexed keywords

DIPHTHERIA TOXOID CRM197; GROWTH FACTOR; HEPARIN; HEPARIN BINDING EPIDERMAL GROWTH FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AORTA ARCH; AORTA WALL; ARTICLE; CANCER GROWTH; CANCER THERAPY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNIZATION; IN VIVO STUDY; LIFESPAN; MALE; MOUSE; NONHUMAN; PROSTATE CARCINOMA; TUMOR GROWTH; TUMOR VOLUME; UMBILICAL VEIN ENDOTHELIAL CELL; VACCINATION; WOUND HEALING;

MURINAE; MUS;

EID: 79951498989     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2010007500145     Document Type: Article

References (36)

1. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
2. Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med 1998; 49: 407-424.
3. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994; 79: 185-188.
4. Folkman J. Fighting cancer by attacking its blood supply. Sci Am 1996; 275: 150-154.
5. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999; 5: 1359-1364.
6. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005; 5: 436-446.
7. Scappaticci FA. Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 2002; 20: 3906-3927.
8. de Gruijl TD, van den Eertwegh AJ, Pinedo HM, Scheper RJ. Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunol Immunother 2008; 57: 1569-1577.
9. Wei YQ, Wang QR, Zhao X, Yang L, Tian L, Lu Y, et al. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 2000; 6: 1160-1166.
10. Yoshiura K, Nishishita T, Nakaoka T, Yamashita N, Yamashita N. Inhibition of B16 melanoma growth and metastasis in C57BL mice by vaccination with a syngeneic endothelial cell line. J Exp Clin Cancer Res 2009; 28: 13.
11. Okaji Y, Tsuno NH, Kitayama J, Saito S, Takahashi T, Kawai K, et al. Vaccination with autologous endothelium inhibits angiogenesis and metastasis of colon cancer through autoimmunity. Cancer Sci 2004; 95: 85-90.
12. Chen XY, Zhang W, Zhang W, Wu S, Bi F, Su YJ, et al. Vaccination with viable human umbilical vein endothelial cells prevents metastatic tumors by attack on tumor vasculature with both cellular and humoral immunity. Clin Cancer Res 2006; 12: 5834-5840.
13. Okaji Y, Tsuno NH, Tanaka M, Yoneyama S, Matsuhashi M, Kitayama J, et al. Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy. Eur J Cancer 2008; 44: 383-390.
14. Uchida T, Gill DM, Pappenheimer AM Jr. Mutation in the structural gene for diphtheria toxin carried by temperate phage. Nat New Biol 1971; 233: 8-11.
15. Giannini G, Rappuoli R, Ratti G. The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197. Nucleic Acids Res 1984; 12: 4063-4069.
16. Qiao J, Ghani K, Caruso M. Diphtheria toxin mutant CRM197 is an inhibitor of protein synthesis that induces cellular toxicity. Toxicon 2008; 51: 473-477.
17. Kageyama T, Ohishi M, Miyamoto S, Mizushima H, Iwamoto R, Mekada E. Diphtheria toxin mutant CRM197 possesses weak EF2-ADP-ribosyl activity that potentiates its antitumorigenic activity. J Biochem 2007; 142: 95-104.
18. Daum RS, Hogerman D, Rennels MB, Bewley K, Malinoski F, Rothstein E, et al. Infant immunization with pneumococcal CRM197 vaccines: effect of saccharide size on immunogenicity and interactions with simultaneously administered vaccines. J Infect Dis 1997; 176: 445-455.
19. Schneider LC, Insel RA, Howie G, Madore DV, Geha RS. Response to a Haemophilus influenzae type b diphtheria CRM197 conjugate vaccine in children with a defect of antibody production to Haemophilus influenzae type b polysaccharide. J Allergy Clin Immunol 1990; 85: 948-953.
20. Buzzi S, Rubboli D, Buzzi G, Buzzi AM, Morisi C, Pironi F. CRM197 (nontoxic diphtheria toxin): effects on advanced cancer patients. Cancer Immunol Immunother 2004; 53: 1041-1048.
21. Yagi H, Yotsumoto F, Sonoda K, Kuroki M, Mekada E, Miyamoto S. Synergistic anti-tumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer. Int J Cancer 2009; 124: 1429-1439.
22. Naglich JG, Metherall JE, Russell DW, Eidels L. Expression cloning of a diphtheria toxin receptor: identity with a heparinbinding EGF-like growth factor precursor. Cell 1992; 69: 1051-1061.
23. Iwamoto R, Higashiyama S, Mitamura T, Taniguchi N, Klagsbrun M, Mekada E. Heparin-binding EGF-like growth factor, which acts as the diphtheria toxin receptor, forms a complex with membrane protein DRAP27/CD9, which up-regulates functional receptors and diphtheria toxin sensitivity. EMBO J 1994; 13: 2322-2330.
24. Yagi H, Miyamoto S, Tanaka Y, Sonoda K, Kobayashi H, Kishikawa T, et al. Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer. Br J Cancer 2005; 92: 1737-1745.
25. Tanaka Y, Miyamoto S, Suzuki SO, Oki E, Yagi H, Sonoda K, et al. Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer. Clin Cancer Res 2005; 11: 4783-4792.
26. Miyamoto S, Yagi H, Yotsumoto F, Kawarabayashi T, Mekada E. Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy. Cancer Sci 2006; 97: 341-347.
27. Miyamoto S, Hirata M, Yamazaki A, Kageyama T, Hasuwa H, Mizushima H, et al. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res 2004; 64: 5720-5727.
28. Mitamura T, Higashiyama S, Taniguchi N, Klagsbrun M, Mekada E. Diphtheria toxin binds to the epidermal growth factor (EGF)-like domain of human heparin-binding EGFlike growth factor/diphtheria toxin receptor and inhibits specifically its mitogenic activity. J Biol Chem 1995; 270: 1015-1019.
29. Angelucci A, Gravina GL, Rucci N, Millimaggi D, Festuccia C, Muzi P, et al. Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocr Relat Cancer 2006; 13: 197-210.
30. Torring N, Jorgensen PE, Sorensen BS, Nexo E. Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines. Anticancer Res 2000; 20: 91-95.
31. Yankai Z, Rong Y, Yi H, Wentao L, Rongyue C, Ming Y, et al. Ten tandem repeats of beta-hCG 109-118 enhance immunogenicity and anti-tumor effects of beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65. Biochem Biophys Res Commun 2006; 345: 1365-1371.
32. Distler JH, Hirth A, Kurowska-Stolarska M, Gay RE, Gay S, Distler O. Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med 2003; 47: 149-161.
33. Kerbel RS. Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000; 21: 505-515.
34. Kerbel RS. A cancer therapy resistant to resistance. Nature 1997; 390: 335-336.
35. Iivanainen E, Nelimarkka L, Elenius V, Heikkinen SM, Junttila TT, Sihombing L, et al. Angiopoietin-regulated recruitment of vascular smooth muscle cells by endothelial-derived heparin binding EGF-like growth factor. FASEB J 2003; 17: 1609-1621.
36. Bates DO, Jones RO. The role of vascular endothelial growth factor in wound healing. Int J Low Extrem Wounds 2003; 2: 107-120.